Riding on the momentum of two licensing deals, Harbour BioMed now has $85 million to advance its freshly beefed up pipeline.

GIC — Singapore’s sovereign wealth fund — led the Series B, leading a syndicate that includes China Life Private Equity Investment and Vertex Ventures as well as Series A investors AdvanTech and Legend Capital.